Olof has an academic background with a Ph.D. Pharmacology and a Postdoc Electrophysiology at Karolinska Institute. He brings a long experience heading up research teams at international companies like Eli Lilly Inc. (US) and Astra Zeneca ranging a number of clinical areas such neurodegenerative diseases.
In times of uncertainty and crisis, clear information saves lives. This is as true on a national level as it is in the clinic.
Walter Campos MBA, MSc, PhD Virology has been promoted to Commercial Director, Africa. Walter has been working with Cavidi since 2012 and most recently served as Operations Director for Africa. In his expanded role Walter will be responsible for Cavidi commercial and distribution management in Africa.
Rain Eriksoo has been appointed CEO of Cavidi. Rain will move Cavidi from a project orientated company focused on product development to a commercial business. Cavidi is currently verifying the new Ziva Analyzer together with the Ziva Viral Load assay. Rain will focus on accelerating the go to market approach to maximise commercial success.
The gene therapy market in the United States is growing rapidly, fueled in part by new gene editing technologies such as CRISPR (Clustered Regularly Interspaced Short Palindromic Repeats). Scaling gene therapy will require a number of new technologies for both researchers and clinicians.
"It was an honour to be nominated especially when one sees the variety of the companies involved and the number of industries" said John Reisky de Dubnic, CEO of Cavidi. "We represent life science which is an important sector in Uppsala but the other nominees were from completely different industries.
Cavidi’s innovation is aimed at closing the gap betweenr the market need for Viral Load and current capabilities for decentralised testing. Our innovation is delivered in three parts: https://www.mynewsdesk.
The Human Immunodeficiency Virus (HIV) has puzzled scientist around the world for decades. Since its discovery in the early 80's the virus has caused one of the worst pandemics the world has seen in modern times.
VP of European Investment Bank Ambroise FAYOLLE presents award for Innovation in Infectious Diseases to John Reisky de Debnic, CEO Cavidi. Cavidi was the first to receive funding with debt placement of €10,000,000 loan from the EIB Venture Debt product.
Cavidi has since mid 2017 received SEK 120 million in new equity funding in two financing rounds. Both investment rounds generated interest from both national and international investors, this allowing the company to select the best among very competent alternatives.